Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (JNJ) announced three-year Phase 3 results for TREMFYA in adults with moderately to severely active Crohn's disease.
At Week 144 in the GALAXI 2 and 3 long-term extensions, clinical remission reached 94% with 100 mg every eight weeks and 91% with 200 mg every four weeks, following intravenous induction. Endoscopic remission, measured by intestinal examination, reached 52% and 61%, respectively. Both regimens achieved 88% 90-day corticosteroid-free clinical remission. Overall, 74% of TREMFYA-treated patients remained on treatment through three years. Safety findings were consistent with the established Crohn's disease safety profile.
The remission rates reflect as-observed data: participants entered the extension, received at least one partial or complete dose, remained on treatment and had Week 144 data. Participants with dose adjustments were excluded.
Johnson & Johnson (JNJ) announced Phase 3 TREMFYA results showing greater fistula remission than placebo across Crohn's disease patient subgroups.
The prespecified FUZION analyses assessed Week 24 combined fistula remission. Previously reported overall rates were 28% with 100 mg injected under the skin every eight weeks and 27% with 200 mg every four weeks, versus 10% with placebo. Among patients with prior biologic exposure, corresponding rates were 21% and 29%, versus 5%. Higher remission rates than placebo were also reported in patients with greater intestinal disease activity and those with or without proctitis, or rectal inflammation.
Remission required closure of all external fistula openings without drainage or new fistulas, and no underlying fluid collections on MRI. Adverse events were consistent with TREMFYA's known Crohn's disease safety profile.
Johnson & Johnson (NYSE: JNJ) announced two-year Phase 3 ICONIC-LEAD results for ICOTYDE in adults and adolescents with moderate-to-severe plaque psoriasis. The study enrolled 684 participants aged 12 or older, including 66 adolescents. At Week 112, ≥72% of ICOTYDE-treated patients achieved PASI 90, meaning at least 90% improvement in psoriasis severity. From Week 64 through Week 112, ≥70% achieved clear or almost clear skin, ≥44% achieved complete clearance by PASI, and ≥46% achieved clear skin on the investigator assessment.
Meaningful itch improvement was sustained in 78% from Week 64 to Week 112. Among PASI 90 responders withdrawn from treatment at Week 24, 85% regained that response within 24 weeks of retreatment. Safety findings through Week 112 were consistent with the established profile, with no new safety signals. ICOTYDE is already approved in the U.S., Europe, Japan and China.
Johnson & Johnson (NYSE: JNJ) announced two-year Phase 3 ICONIC-TOTAL results showing sustained skin clearance with ICOTYDE in high-impact plaque psoriasis sites.
The study evaluated adults and adolescents with at least moderate scalp, genital and/or hand/foot involvement. Clear or almost clear skin rates rose from 57% at Week 16 to 67% at Week 24 and 70% at Week 112. At Week 112, complete site-specific clearance reached 60% for scalp, 89% for genital and 63% for hand and/or foot psoriasis. Mean improvement in the modified Nail Psoriasis Severity Index, a measure of nail disease severity, increased from 33% at Week 16 to 62% at Week 52 and 71% at Week 112.
No new safety signals were identified through Week 112. The study compared once-daily ICOTYDE with placebo, with placebo patients transitioning to ICOTYDE at Week 16.
Johnson & Johnson (JNJ) released a global survey showing that 40% of women connect eye changes with the menopause transition. The survey covered 6,000 women across six countries. While 75% have taken action to manage midlife changes, only 18% have booked an annual eye exam as part of that routine. Dry, gritty or irritated eyes were reported by 66%, and blurred vision by 60%; only 18% have discussed these changes with an eye care professional.
The company is continuing its collaboration with Naomi Watts during Menopause Awareness Month, with support from the American Optometric Association, to encourage eye exams and conversations about midlife vision changes. Watts was compensated for her quote.
Johnson & Johnson (JNJ) reported two-year IMAAVY findings in adolescents with generalized myasthenia gravis alongside an adult treatment-switch survey.
In the ongoing Phase 2/3 Vibrance-MG study, adolescents with anti-AChR-positive disease maintained improvements in daily function and muscle strength through Week 108. Among those with available data, mean changes from baseline were −2.88 points on the daily-function scale and −8.25 points on the muscle-strength scale. Of six adolescents taking corticosteroids at study entry, three reduced their dose and one discontinued treatment after two years on IMAAVY. No new safety signals were identified through up to two years of treatment.
In a retrospective clinician survey covering 97 adults who switched from prior advanced therapies to IMAAVY, 73.2% were reported as much or very much improved. Among patients receiving prednisone, 76.4% reduced their dose and 5.5% discontinued it.
Johnson & Johnson (JNJ) reported that TREMFYA met its primary and major secondary endpoints in the Phase 4 STAR axial psoriatic arthritis study. At Week 24, it met the primary endpoint for improvement versus placebo in BASDAI, a patient-reported disease activity score that includes spinal pain and stiffness. Major secondary endpoints showed reductions in axial symptoms measured by ASDAS-CRP and in sacroiliac-joint inflammation measured by MRI.
The randomized, double-blind, placebo-controlled study enrolled 411 biologic-naïve adults with active psoriatic arthritis and MRI-confirmed axial inflammation. Its 24-week placebo-controlled period is followed by 24 weeks of active treatment. The observed safety profile was consistent with TREMFYA’s established profile in psoriatic arthritis, with no new safety signals identified. Detailed efficacy and safety results, including MRI findings, are due at an upcoming scientific congress.
Johnson & Johnson (JNJ) reported five-year CARTITUDE-2 data showing 10 of 20 CARVYKTI-treated patients alive and progression-free without maintenance therapy. The Phase 2 cohort included patients with relapsed or refractory multiple myeloma who had received one to three prior lines of treatment. At a median follow-up of 60.7 months, the five-year overall survival rate was 69.2%, and median progression-free survival was 60.5 months.
Patients received one CARVYKTI infusion. At five years, three patients underwent bone-marrow testing for minimal residual disease, meaning cancer cells undetectable by the test used; all three tested negative at the deepest level measured. Testing was not required by the study protocol. Since the previous analysis, one patient developed acute myeloid leukemia, and two deaths occurred due to progressive disease and new cancer. No new CAR T-cell-related neurotoxicity was reported.
Johnson & Johnson (JNJ) reported new MajesTEC-3 analyses showing TECVAYLI plus DARZALEX FASPRO markedly improves outcomes in relapsed/refractory multiple myeloma.
Using a relative survival mixture cure model in patients with 1–3 prior lines of therapy, ~87% of those treated with the combination were estimated to have mortality risk and projected life expectancy similar to an age‑matched general population. Best‑fit modeling estimated an OS “cure fraction” of 86.6% versus 0% with pomalidomide- or bortezomib‑based standard of care and projected remaining life expectancy of 18.5 years versus 4.9 years.
A post hoc competing‑risk analysis showed a 90% reduction in disease‑progression risk at 36 months (8.7% vs 62.1% cumulative incidence) and 36‑month OS of 83.3% vs 65.0%, without a significant increase in non‑relapse mortality. MajesTEC-3 follow‑up is ongoing, and the company notes these long‑term projections remain model‑based.
DePuy Synthes (JNJ) will showcase next-generation trauma innovations at the 2026 Orthopaedic Trauma Association Annual Meeting in Nashville. The company is highlighting four new VOLT™ plating systems that expand its Variable Angle Optimized Locking Technology portfolio for fracture fixation across the ankle, knee and shoulder, designed using MOSAIC™ technology to improve implant fit across diverse anatomies.
DePuy Synthes is also presenting the MAXFRAME AUTOSTRUT™ with Bluetooth® Multi-Axial Correction System, now commercially available in the U.S. and described as combining automated device adjustments with real-time remote monitoring for complex limb reconstruction. A new VELYS™ Trauma AI-Assisted Surgery technology for intraoperative 3D guidance in fracture care is planned to launch in the U.S. in 2027, alongside an expanded soft tissue and biologics portfolio and demos of the SOURCEVIEW™ Analytics Platform.